Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Terminated 1Recruiting 1No longer available 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1CNS 1

Conditions

Gliosarcoma 1Glioblastoma 1

Interventions

Temozolomide 79Magnetic Resonance Spectroscopy 68Specimen Handling 45Radiotherapy 42Bevacizumab 29Radiosurgery 27Cyclophosphamide 27Radiation 20pembrolizumab 19Blood Specimen Collection 19fludarabine 16Nivolumab 16Irinotecan 15Carboplatin 13Biopsy 13Etoposide 12Vincristine 11Pemetrexed 11Lomustine 11dinutuximab 9Surgical Procedures, Operative 9trametinib 8abemaciclib 8Ipilimumab 8naxitamab 7fluciclovine F-18 7Watchful Waiting 7Topotecan 7Proton Therapy 7Magnetic Resonance Imaging 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × efineptakin alfa × CNS × Clear all
NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Mayo Clinic

Phase 2 Recruiting
54 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡